New Medication Aims to Re-Myelinate the Optic Nerve after Optic Neuritis8:58 AM
There is never a shortage of hope in the pharmaceutical world, and the recent reports on anti-LINGO-1(Biogen Idec) are full of promise for patients that have suffered vision loss from optic neuritis events. The drug targets the LINGO-1 protein that is found in the human central nervous system and is known to inhibit myelination of axons and regeneration of axons. Myelin is the important sheathing found along axons to speed transmission of information along the nerve. By blocking LINGO-1, the medication hopes to promote myelin production and potentially regenerate axon tissue -- a benefit that if successful could find uses in medical conditions from MS to Alzheimer's.
|LINGO-1 protein via|
|VEP testing is used to measure transmission of information|
from the eye to the brain based on responses to patterned
images at the level of your visual cortex. If your brain
responds to the image (measured with electrodes placed
in the area), then we know exactly when your brain "sees"
the image via